DJIA 16,979.13 59.54 0.35%
NASDAQ 4,526.48 -1.03 -0.02%
S&P 500 1,986.51 4.91 0.25%
market minute promo

GlaxoSmithKline (NYSE: GSK)

47.81 0.46 (0.97%)

REAL-TIME: Last trade at

Extended Hours: $47.91 $0.10 (0.21%)
Quote as of (NYSE)



company name or ticker

Recent Quotes

GSK $47.81 0.97%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $47.48
Previous Close $47.35
Daily Range $47.30 - $47.83
52-Week Range $46.01 - $56.73
Market Cap $114.8B
P/E Ratio 16.27
Dividend (Yield) $2.59 (5.6%)
Ex-Dividend Date
Dividend Pay Date
08/06/14
10/02/14
Volume 5,286,727
Average Daily Volume 4,295,311
Current FY EPS $3.20

Sector

Healthcare

Industry

Drugs

GlaxoSmithKline (GSK) Description

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Website: http://www.gsk.com/

News & Commentary Rss Feed

3 Reasons GlaxoSmithKline plc Stock Could Rise

GlaxoSmithKline's transition period has been far rougher than expected, causing shares to drop nearly 15% last quarter. Even so, there are three compelling reasons to believe that shares could rally heading into the end of the year.

Novartis to Invest $35M in Gamida Cell for 15% Equity - Analyst Blog

Novartis to Invest $35M in Gamida Cell for 15% Equity - Analyst Blog

Closing Update: Stocks Scratch Out Small Gains After Fed Minutes Point to Eventual Rate Moves

Sector Update: Health Care Stocks Rebound Late; Amicus Therapeutics Gives Up Much of Wednesday Advan

Sector Update: Health Care Stocks Rebound Late; Amicus Therapeutics Gives Up Much of Wednesday Advance

UPDATE: GlaxoSmithKline Receives FDA Approval For Arnuity Ellipta In US For Treatment Of Asthma

Why Mylan (MYL) Stock Is Advancing Today

Eurozone Recovery Stalls in Q2: 3 Stocks to Sell Now - Analyst Blog

If You Want Dividend Income, Look No Further than GlaxoSmithKline plc Stock

GlaxoSmithKline's focus on these two therapeutic areas could be the impetus that pushes its payout higher and puts ample dividend income in shareholders' pockets.

Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win

GlaxoSmithKline: To Buy Or Not To Buy?

See More GSK News...

GSK's Top Competitors

GSK $47.81 (0.97%)
Current stock: GSK
RHHBY $36.45 (-0.52%)
Current stock: RHHBY
JNJ $103.21 (0.24%)
Current stock: JNJ
PFE $28.89 (-0.17%)
Current stock: PFE